Silo Pharma (SILO) Income from Non-Controlling Interests (2011 - 2023)

Silo Pharma (SILO) posted Income from Non-Controlling Interests of $1.0 million for Q2 2023, up 11.76% sequentially from $906396.0 in Q1 2023.

Silo Pharma (SILO) Income from Non-Controlling Interests (2011 - 2023) Analysis & Trends

Silo Pharma has reported Income from Non-Controlling Interests for 3 years, with the latest figure at $1.0 million in Q2 2023.

Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $1.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4.6 million (changed N/A YoY) and the FY2022 annual result came in at $3.9 million, changed N/A from the prior year.
Income from Non-Controlling Interests climbed to $1.0 million in Q2 2023 per SILO's latest filing, from $906396.0 in the prior quarter.
Over five years, Income from Non-Controlling Interests peaked at $1.7 million in Q4 2022 and troughed at $906396.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inc. Minority (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	63.60 Mn
10	Silo Pharma	2.92 Mn	2.92 Mn	-	-

Download Data